These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 11086633

  • 21. Angiotensin II type 1 receptor blockers.
    Burnier M.
    Circulation; 2001 Feb 13; 103(6):904-12. PubMed ID: 11171802
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Improving prognosis in hypertension: exploring the benefits of angiotensin II type 1 receptor blockade.
    Ruilope L.
    Blood Press Suppl; 2000 Feb 13; 1():31-5. PubMed ID: 11059634
    [Abstract] [Full Text] [Related]

  • 24. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S, Stirling AL.
    Am J Health Syst Pharm; 2000 Apr 15; 57(8):739-46. PubMed ID: 10786259
    [Abstract] [Full Text] [Related]

  • 25. Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats.
    Rizzoni D, Porteri E, Bettoni G, Piccoli A, Castellano M, Muiesan ML, Pasini G, Guelfi D, Rosei EA.
    J Cardiovasc Pharmacol; 1998 Nov 15; 32(5):798-806. PubMed ID: 9821855
    [Abstract] [Full Text] [Related]

  • 26. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA, McVoy HJ, Kaul AF.
    Ann Pharmacother; 1999 Dec 15; 33(12):1287-98. PubMed ID: 10630830
    [Abstract] [Full Text] [Related]

  • 27. Angiotensin II receptor antagonist TCV-116 induces regression of hypertensive left ventricular hypertrophy in vivo and inhibits the intracellular signaling pathway of stretch-mediated cardiomyocyte hypertrophy in vitro.
    Kojima M, Shiojima I, Yamazaki T, Komuro I, Zou Z, Wang Y, Mizuno T, Ueki K, Tobe K, Kadowaki T.
    Circulation; 1994 May 15; 89(5):2204-11. PubMed ID: 8181146
    [Abstract] [Full Text] [Related]

  • 28. Differences among angiotensin II type 1 receptor blockers: characteristics of candesartan cilexetil.
    Unger T.
    Blood Press Suppl; 2000 May 15; 1():14-8. PubMed ID: 11059630
    [Abstract] [Full Text] [Related]

  • 29. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?
    Grossman E, Messerli FH, Neutel JM.
    Arch Intern Med; 2000 Jul 10; 160(13):1905-11. PubMed ID: 10888965
    [No Abstract] [Full Text] [Related]

  • 30. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
    Bönner G, Fuchs W.
    Curr Med Res Opin; 2005 Jun 10; 21(6):935-40. PubMed ID: 15969893
    [Abstract] [Full Text] [Related]

  • 31. [Angiotensin receptor antagonist for therapy of patients with hypertension].
    Rakugi H, Ogihara T.
    Nihon Rinsho; 1997 Aug 10; 55(8):2075-80. PubMed ID: 9284426
    [Abstract] [Full Text] [Related]

  • 32. Transcriptomic Response in the Heart and Kidney to Different Types of Antihypertensive Drug Administration.
    Takeuchi F, Liang YQ, Isono M, Ang MY, Mori K, Kato N.
    Hypertension; 2022 Feb 10; 79(2):413-423. PubMed ID: 34879704
    [Abstract] [Full Text] [Related]

  • 33. Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats.
    Cervenka L, Wang CT, Navar LG.
    Am J Physiol; 1998 May 10; 274(5):F940-5. PubMed ID: 9612332
    [Abstract] [Full Text] [Related]

  • 34. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K, Kahan T, Dahl M.
    Am J Hypertens; 2000 May 10; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [Abstract] [Full Text] [Related]

  • 35. Significance of angiotensin type 1 receptor blockade: why are angiotensin II receptor blockers different?
    Unger T.
    Am J Cardiol; 1999 Nov 18; 84(10A):9S-15S. PubMed ID: 10588089
    [Abstract] [Full Text] [Related]

  • 36. Angiotensin-II receptor antagonists: their place in therapy.
    Kirk JK.
    Am Fam Physician; 1999 Jun 18; 59(11):3140-8. PubMed ID: 10392595
    [Abstract] [Full Text] [Related]

  • 37. Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.
    Sepehrdad R, Frishman WH, Stier CT, Sica DA.
    Cardiol Rev; 2007 Jun 18; 15(5):242-56. PubMed ID: 17700383
    [Abstract] [Full Text] [Related]

  • 38. Hypotensive activity of TCV-116, a newly developed angiotensin II receptor antagonist, in spontaneously hypertensive rats.
    Mizuno K, Niimura S, Tani M, Saito I, Sanada H, Takahashi M, Okazaki K, Yamaguchi M, Fukuchi S.
    Life Sci; 1992 Jun 18; 51(20):PL183-7. PubMed ID: 1435062
    [Abstract] [Full Text] [Related]

  • 39. Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess.
    Susic D, Varagic J, Frohlich ED.
    Am J Physiol Heart Circ Physiol; 2010 Apr 18; 298(4):H1177-81. PubMed ID: 20118410
    [Abstract] [Full Text] [Related]

  • 40. Comparison between the angiotensin II receptor antagonist candesartan cilexetil and the angiotensin-converting enzyme inhibitor trandolapril in microalbuminuria of patients with early diabetic nephropathy.
    Nakamura T, Ushiyama C, Suzuki S, Shimada N, Sekizuka K, Ebihara I, Takahashi Y, Tanaka A, Koide H.
    Nephron; 2000 Oct 18; 86(2):247. PubMed ID: 11015024
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.